Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease

Movement Disorders

Volumn 30, Issue 7, 2015, Pages 945-952

  Castellanos, Gabriel ^a,b   Fernández Seara, María A ^a,b   Lorenzo Betancor, Oswaldo ^a,b   Ortega Cubero, Sara ^a,b   Puigvert, Marc ^d   Uranga, Javier ^c   Vidorreta, Marta ^a   Irigoyen, Jaione ^a,b,d   Lorenzo, Elena ^a   Muñoz Barrutia, Arrate ^c,f   Ortiz de Solorzano, Carlos ^c   Pastor, Pau ^a,b,d,e   Pastor, María A ^a,b,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f UNIVERSIDAD CARLOS III DE MADRID   (Spain)

Author keywords

Diagnosis; Magnetic resonance imaging; Neuromelanin; Parkinson's; Substantia nigra

Indexed keywords

BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; NEUROMELANIN; PARKIN; MELANIN;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOCUS CERULEUS; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SEX RATIO; UNIFIED PARKINSON DISEASE RATING SCALE; VOLUMETRY; MIDDLE AGED; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; STANDARDS; SUBSTANTIA NIGRA;

AGED; BIOMARKERS; FEMALE; HUMANS; LOCUS COERULEUS; MAGNETIC RESONANCE IMAGING; MALE; MELANINS; MIDDLE AGED; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84931955307     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26201     Document Type: Article

References (48)

1. Halliday GM, Ophof A, Broe M, et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128:2654-2664.
2. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009;201:1-119.
3. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218.
4. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633-1638.
5. Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093-1096.
6. Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719-724.
7. Ohtsuka C, Sasaki M, Konno K, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Neurosci Lett 2013;541:93-98.
8. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011;68:22-30.
9. Lehéricy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27:822-830.
10. Artaechevarria X, Munoz-Barrutia A, Ortiz-de-Solorzano C. Combination strategies in multi-atlas image segmentation: application to brain MR data. IEEE Trans Med Imaging 2009;28:1266-1277.
11. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27:831-842.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
13. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298.
14. Zou KH, Yu CR, Liu K, Carlsson MO, Cabrera J. Optimal thresholds by maximizing or minimizing various metrics via ROC-type analysis. Acad Radiol 2013;20:807-815.
15. Dujardin B, Van den Ende J, Van Gompel A, Unger JP, Van der Stuyft P. Likelihood ratios: a real improvement for clinical decision making? Eur. J. Epidemiol. 1994;10:29-36.
16. Brown MD, Reeves MJ. Interval likelihood ratios: another advantage for the evidence-based diagnostician. Ann Emerg Med 2003;42:292-297.
17. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500-1506.
18. Provost F, Fawcett T. Robust classification for imprecise environments. Mach Learn 2001;42:203-231.
19. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol 2006;5:796-802.
20. Lehéricy S, Bardinet E, Poupon C, Vidailhet M, François C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov. Disord. 2014;13:1574-1581.
21. Kempster PA, Gibb WR, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989;52:72-76.
22. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132:2970-2979.
23. Van de Loo S, Walter U, Behnke S, et al. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81:1087-1092.
24. McNeill A, Wu RM, Tzen KY, et al. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLoS One 2013;8:e69190.
25. Baudrexel S, Nürnberger L, Rüb U, et al. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 2010;51:512-520.
26. Martin WRW, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-1417.
27. García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C. L et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013;136:2120-2129.
28. Du G, Lewis MM, Styner M, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627-1632.
29. Prodoehl J, Li H, Planetta PJ, et al. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord 2013;28:1816-1822.
30. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The "swallow tail" appearance of the healthy nigrosome-a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814.
31. Kitao S, Matsusue E, Fujii S, et al. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Neuroradiology 2013;55:947-953.
32. Kuramoto L, Cragg J, Nandhagopal R, et al. The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One 2013;8:e76595.
33. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011;134:3290-3298.
34. Matsuura K, Maeda M, Yata K, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013;70:70-77.
35. Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755-760.
36. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010;133:1128-1142.
37. Hoogendijk WJ, Pool CW, Troost D, van Zwieten E, Swaab DF. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995;118:131-143.
38. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
39. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500-508.
40. Adler CH, Beach TG, Shill HA, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease. Neurology 2014;83:406-412.
41. Lee CS, Schulzer M, de la Fuente-Fernández R, et al. Lack of regional selectivity during the progression of Parkinson disease. Arch Neurol 2004;61:1920-1925.
42. Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013;70:571-579.
43. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514.
44. German DC, Manaye KF, White CL, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992;32:667-676.
45. Eriksen N, Stark AK, Pakkenberg B. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta. J Neural Transm Suppl 2009;73:203-213.
46. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
47. Simel DL, Keitz S. Update: primer on precision and accuracy. In: Simel D, Rennie D, editors. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. New York: McGraw-Hill Medical; 2008:9-16.
48. Shibata E, Sasaki M, Tohyama K, et al. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol Psychiatry 2008;64:401-406.